文献速递前列腺癌

前列腺癌抗原3评分不能预测中高危局限性前列腺癌根治术后的不良病理特征或无进展生存

Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
PubMed 文献 · Urology · 2017-05-25

回顾性纳入109例中危(52例)或高危(57例)前列腺癌根治术患者,评估术前尿PCA3评分与不良病理特征及无进展生存的关系。多因素分析显示PCA3不是任何不良病理特征或无进展生存的显著预测因子,而活检Gleason评分、初始PSA等经典预测因子仍有预测作用。作者认为PCA3可能不是中高危前列腺癌的有用辅助预测标志物。

要点

  • 在中危或高危前列腺癌队列中,PCA3评分与不良病理特征无显著关联。
  • PCA3评分与无进展生存无显著关联,单因素和多因素分析均不显著。
  • 活检Gleason评分和初始PSA等多因素分析仍可预测不良病理特征。

核心结论

  • 与较低危队列不同,在中危或高危前列腺癌队列中,尽管不良病理特征富集,PCA3评分升高与任何不良病理特征均无关联,也与无进展生存无关联。
  • 多个已知的术前不良病理特征预测因子在多因素分析中显著,多个预测因子在单因素分析中与无进展生存相关。
  • 作者认为PCA3可能不是中危或高危前列腺癌男性的有用辅助预测标志物。

研究设计与样本

  • 回顾性识别109例接受根治性前列腺切除术的中危(n=52)或高危(n=57)前列腺癌男性。
  • 采用逻辑回归分析评估PCA3评分与各种不良病理特征(如包膜外侵犯、精囊侵犯等)的关联。
  • 在78例随访≥1年的男性中,采用Cox回归分析评估PCA3评分与无进展生存的关联。

主要发现

  • 根治性前列腺切除术时,52%的患者至少有1项不良病理特征。
  • 中位随访2.3年,总体3年无进展生存率为70%。
  • 多因素分析中,PCA3不是任何不良病理特征的显著预测因子,而经典预测因子(如活检Gleason评分和初始前列腺特异性抗原)仍可预测各种不良病理特征。
  • 多因素分析未发现无进展生存的显著预测因子,尽管某些经典预测因子(如美国国家综合癌症网络风险分组)在单因素分析中是無进展生存的显著预测因子。
  • PCA3评分在单因素和多因素分析中均不是无进展生存的显著预测因子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether preoperative urinary prostate cancer antigen 3 (PCA3) scores predict for adverse pathologic features (APFs) or progression-free survival (PFS) in men with intermediate- or high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). MATERIALS AND METHODS: One hundred nine men with intermediate- (n = 52) or high-risk (n = 57) PCa who underwent RP were retrospectively identified. Logistic regression analysis was performed to evaluate the association of PCA3 score with various APFs (eg, extracapsular extension, seminal vesicle invasion, etc.). Among 78 men with ≥1 year of follow-up, the association between PCA3 score and PFS was assessed using Cox regression analysis. RESULTS: At RP, 52% of patients had at least 1 APF, and with median follow-up of 2.3 years, overall 3-year PFS was 70%. PCA3 was not a significant predictor of any APF on multivariate analysis (MVA), whereas canonical predictors (eg, biopsy Gleason score and initial prostate-specific antigen) remained predictive of various APFs. No significant predictors for PFS were found on MVA, although certain canonical predictors (eg, National Comprehensive Cancer Network risk group) were significant predictors of PFS on univariate analysis (UVA). PCA3 score was not a significant predictor of PFS on either UVA or MVA. CONCLUSION: Unlike in lower risk cohorts, increasing PCA3 score was not associated with any APF in this higher risk cohort, despite enrichment for APFs, nor was it associated with PFS. Notably, multiple known preoperative predictors for APFs were significant on MVA, and multiple predictors were associated with PFS on UVA. Therefore, PCA3 may not be a useful adjunct predictive marker in men with intermediate- or high-risk PCa.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Hegde JV, Veruttipong D, Said JW, et al. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. Urology. 2017. PMID: 28552819. doi:10.1016/j.urology.2017.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。